Strides Pharma Science Limited has informed the Exchange regarding a revised press release dated October 03, 2023, titled "This has reference to the Press Release issued by the Company on September 23, 2023 titled as Strides receives USFDA approval for Icosapent Ethyl Capsules The said press release has been updated with some additional information on the Product and the revised Press release is attached herewith for your records.".
Press Release (Revised) Oct 03 2023
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Strides Pharma Science Ltd has issued an updated press release regarding its recent USFDA approval for Icosapent Ethyl Capsules. The revised press release includes additional information about the product and its market opportunity. The capsules are bioequivalent to the reference drug and will be manufactured at the company's facility in Bengaluru. Strides aims to launch a significant number of new products in the US market over the next few years.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Press Release Sep 23 2023
- Intimation of Board Meeting scheduled on Sept 25, 2023
- Press Release Sep 14 2023
- Press Release Sep 09 2023
- Press Release Aug 30 2023
Later from Strides Pharma Science
- Press Release Oct 04 2023
- Press Release Oct 30 2023
- Press Release Nov 21 2023
- Strides Pharma Science Ltd Press Release Nov 23 2023
- Press Release Dec 01 2023
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science